Trade BioNTech BNTX

BioNTech live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

number1 2025 Dec 05, 00:01

Pimco's Triumph in 2025: A Bold Bond Strategy Pays Off

number1 2025 Dec 04, 00:00

Fed Independence on the Line? Political Influence in 2026

number1 2025 Dec 04, 00:00

US Holiday Shopping Season: Record Online Sales Amid Economic Vulnerabilities

number1 2025 Dec 03, 00:00

US Economic Outlook 2026: A Roubini Analysis

number1 2025 Dec 02, 00:01

Fed's Divergent Votes: A Sign of Policy Uncertainty?

Frances Wang 2024 Dec 29, 16:00

Trading wisdom: how can I improve myself as a trader?

Frances Wang 2024 Dec 26, 16:00

Can you trade CFDs on crypto: platform to trade cryptocurrency CFDs

Frances Wang 2024 Dec 25, 16:00

EQV stock price today: Is EQV Ventures a good investment?

Frances Wang 2024 Dec 25, 16:00

How to start investing in dividend ETFs: 7 Dividend ETFs to Watch

Frances Wang 2024 Dec 23, 16:00

TSLQ ETF price forecast: How to track TSLQ ETF prices?

Latest news

Show more
number1 2025 Dec 06, 00:00

India's Silver Demand Surge: New Loan Framework Boosts Market

number1 2025 Dec 04, 00:00

ADP Employment Data and the Fed's Policy Path: A Closer Look

number1 2025 Dec 03, 00:00

Silver and Gold Market Analysis: A Look at the Post-Rally Correction

number1 2025 Dec 02, 00:00

Starmer Defends Budget Amidst Misleading Claims: 'UK Back on Track'

number1 2025 Dec 02, 00:00

UBS Analysis: Swiss National Bank Likely Didn't Intervene in FX Market in October

number1 2025 Nov 29, 00:00

CME Outage Disrupts Global Markets, Sparks Trader Frustration

number1 2025 Nov 29, 00:00

Gold & Silver Outlook: Fed Rate Cut Expectations & Uncertainty Loom

number1 2025 Nov 29, 00:00

US-Russia-Ukraine Peace Plan: Deadlock Amidst Western Discord

Info

Spread

0.9666

Spread (%)

1.0109 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

23083724800

Shares Outstanding

240455450

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2.78

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest Education Articles

Show more
Trustpilot